JESSICA SINCLAIR: Open Payments
NPI 1891148011 · MADISON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$855 in 49 payments from 12 companies in 2025. Trend: 2023 $370 · 2024 $520 · 2025 $855
Food & beverage: $855
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 13 | $194 |
| ABBVIE INC. | 14 | $177 |
| Phathom Pharmaceuticals, Inc. | 4 | $152 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $54 |
| Amgen Inc. | 3 | $52 |
| Novo Nordisk Inc | 3 | $51 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $49 |
| Abbott Laboratories | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
| AstraZeneca Pharmaceuticals LP | 1 | $23 |
Products named: MOUNJARO, VOQUEZNA, UBRELVY, QULIPTA, XIFAXAN, VRAYLAR, OTEZLA, CAPLYTA.
Industry payments across MS — which companies pay providers there.
